Correlates of SARS-CoV-2 Breakthrough Infections in Kidney Transplant Recipients Following a Third SARS-CoV-2 mRNA Vaccine Dose
Authors:
- Miriam Viktov ThygesenMTMiriam Viktov Thygesen
- Charlotte StrandhaveCSCharlotte Strandhave
- Jeanette Mølgaard KiibJKJeanette Mølgaard Kiib
- Randi BergRBRandi Berg
- Malene Söth AndersenMAMalene Söth Andersen
- Emma Berggren DallEDEmma Berggren Dall
- Bodil Gade HornstrupBHBodil Gade Hornstrup
- Hans Christian ØstergaardHØHans Christian Østergaard
- Frank Holden MoseFMFrank Holden Mose
- Jon Waarst GregersenJGJon Waarst Gregersen
- Søren Jensen-FangelSJSøren Jensen-Fangel
- Jesper Nørgaard BechJBJesper Nørgaard Bech
Open Access
Abstract
Background: Kidney transplant recipients (KTRs) exhibit a significantly diminished immune response to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) vaccines compared with the general population, primarily due to ongoing immunosuppressive therapy. This study evaluated the immunogenicity of a third SARS-CoV-2 mRNA vaccine dose in KTRs and assessed the association between antibody response and protection against SARS-CoV-2 breakthrough infection. Additionally, the clinical and immunological correlates of post-vaccination SARS-CoV-2 infection were examined. Methods: A prospective cohort of 135 KTRs received a third vaccine dose approximately six months following the second dose. Plasma samples were collected at baseline (pre-vaccination), six months after the second dose, and six weeks following the third dose. Humoral responses were assessed using SARS-CoV-2-specific Immunoglobulin G (IgG) titers and virus neutralization assays against wild-type (WT) and viral strains, including multiple Omicron sub-lineages. Results: After the third vaccine dose, 74% of the KTRs had detectable SARS-CoV-2-specific IgG antibodies, compared with 48% following the second dose. The mean IgG titers increased approximately ten-fold post-booster. Despite this increase, neutralizing activity against the Omicron variants remained significantly lower than that against the WT strain. KTRs who subsequently experienced a SARS-CoV-2 breakthrough infection demonstrated reduced neutralizing antibody activity across all variants tested. Additionally, individuals receiving triple immunosuppressive therapy had a significantly higher risk of SARS-CoV-2 breakthrough infection compared with those on dual or monotherapy. A multivariate machine learning analysis identified age and neutralizing activity against WT, Delta, and Omicron BA.2 as the most robust correlates of SARS-CoV-2 breakthrough infection. Conclusions: A third SARS-CoV-2 mRNA vaccine dose significantly improves SARS-CoV-2-specific IgG levels in KTRs; however, the neutralizing response against Omicron variants remains suboptimal. Diminished neutralizing capacity and intensified immunosuppression are key determinants of SARS-CoV-2 breakthrough infection in this immunocompromised population.Keywords
Funding Information
- Augustinus Fonden
- Toyota fonden
- Grosserer L.F. Foghts Fond
- KV Fonden
This publication has 32 references indexed in Scilit:
- Serological responses and clinical outcomes following a three‐dose primary COVID‐19 vaccine schedule in kidney transplant recipients and people on dialysisClinical & Translational Immunology, 2024
- Humoral vaccine response and breakthrough infections in kidney transplant recipients during the COVID-19 pandemic: a nationwide cohort studyeClinicalMedicine, 2023
- Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipientsAmerican Journal of Transplantation, 2023
- Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysisInternational Urology and Nephrology, 2023
- Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infectionsNature Communications, 2022
- Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipientsKidney International, 2022
- Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant RecipientsTransplantation Proceedings, 2022
- Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escapeNature Reviews Immunology, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- Random ForestsMachine Learning, 2001